Celularity

Update in progress

CELU (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Celularity Inc. is a regenerative and cellular medicines company focused on aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapies, including mesenchymal-like cells, for conditions like diabetic foot ulcers and Crohn’s disease. It operates in Cell Therapy, Degenerative Disease, and BioBanking, with programs PDA-001, PDA-002, and pExo-001, plus wound-care products and LifebankUSA banking. It partners with Sorrento for CD19 CAR-T and with Regeneron for allogeneic cell therapy research. Founded 1998, Florham Park, NJ.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.03; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive